Story

The Full Story

Between 2022 and 2025 the story changed fundamentally: Novozymes went from a self-described "pure-play enzymes" company to Novonesis, a 4.2 bn EUR biosolutions platform built on the largest merger in Danish history. Management has so far delivered what it promised for the combination — cost synergies hit 100% run-rate a year early, every quarterly outlook has been met or raised until the very last one, and the single-year narrative is clean. The quieter subplots are less tidy: the 2022 vintage "double sales by 2030" promise has been retired and replaced with a more modest 6–9% CAGR GROW strategy, adjusted ROIC including goodwill has halved from the pre-merger 18% range to 5.6%, net debt has tripled since 2023 to 1.9x EBITDA after the 1.5 bn EUR Feed Enzyme Alliance buy-out, and Q4 2025 became the first quarter to undershoot consensus. Credibility is intact but no longer unconditional.

1. The Narrative Arc

The revenue line tells the arc visually: three years of mid-single-digit growth (5–9% organic) inside a 2.0 bn EUR company, then a step-change in 2024 when Chr. Hansen consolidates, then a full year of execution at 4.2 bn EUR. The pro forma view reveals the underlying business was growing 7% organically before and after the combination — management's claim that scale did not dilute growth is, so far, supported by the numbers.

2. What Management Emphasized — and Then Stopped Emphasizing

The clearest way to read this company is by what disappeared from the CEO letter between 2022 and 2025.

The heatmap makes three patterns unmistakable:

• The 2022–2023 financial framework was retired silently. The pre-merger promise — 5%+ organic CAGR, 26%+ EBIT margin, 20%+ ROIC including goodwill, and "double sales by 2030 vs. 2020" — has simply disappeared from the 2024 and 2025 reports. No walk-back, no "previous targets achieved / superseded" footnote. It was quietly replaced with 2030 GROW targets (6–9% organic, ~39% EBITDA margin, ~16% ROIC excluding goodwill), announced in August 2025. The goodwill-exclusion matters: on a like-for-like basis ROIC now runs at 5.6% including goodwill, a long way from the old 20% bar.
• "Explore — carbon capture, PET recycling, biological plastic, precision fermentation" was a signature theme of the Novozymes 2022 letter. It has faded by 2024. Saipem carbon-capture and Carbios PET recycling are name-checked less each year; the 2025 CEO letter leads on AI in R&D instead.
• The operating KPI changed. Through 2022–2023 the headline profit number was EBIT margin before special items (target 26%). Post-merger the headline is adjusted EBITDA margin (a different animal — it excludes PPA depreciation, amortization, and integration special items, and therefore strips out the cost of the deal). EBIT margin on IFRS basis went from 26% pre-merger to 13–20% post-merger; adjusted EBITDA margin held at 36–37%. The KPI shift is economically defensible but it also flatters the story.

3. Risk Evolution

What became more important: currency (H1 2025 raised the EBITDA margin guide specifically to "despite strong currency headwinds," and Q3/Q4 2025 commentary is dominated by USD drag); tariffs (first mentioned as a 2025/2026 outlook caveat, now material to planning); and leverage (NIBD/EBITDA ran at 1.0x through 2022, ended 2025 at 1.9x after the Feed Enzyme Alliance bridge loan, peaked at 2.1x intra-year).

What disappeared: "Volatility of agriculture-related business" was a top-four risk in every Novozymes report from 2022 and 2023 — it vanishes from the 2024 risk grid. This is not that the agriculture cycle got safer; it is that the combined company is more diversified (Food & Beverages + Human Health are now 45% of sales), so ethanol / BioAg volatility became less existential and was folded into "Volatility in energy and raw material prices."

What appeared: integration risk (new 2023, peaked 2024, receding in 2025 as synergies hit 100% run-rate) and, more recently, the Russia/Belarus exit narrative — first disclosed at Q4 2024 as "exit from certain countries" (sub-footnote), now recurring in every 2025 quarter because it is the reason the group's reported organic growth is running 1–2 percentage points below the "ex-exit" figure the company prefers to cite.

4. How They Handled Bad News

For a company whose story is dominated by a transformational merger, genuine misses have been rare — and that itself is meaningful evidence about both execution and narrative management.

The pattern: management does not hide misses but it does not concede them either. The 2022 food-gain shortfall was reported cleanly. The 2023 growth deceleration was reframed as the right context for the Chr. Hansen combination. The dramatic 2024 IFRS EPS and ROIC compression was de-emphasized by shifting the headline KPI and attributing the drag to PPA amortization — technically correct, but it means investors looking at the clean adjusted number are underweighting the fact that ~1 bn EUR of goodwill and intangibles now sits on the balance sheet. The Q4 2025 miss is the first event that analysts have treated as a miss rather than a bookkeeping matter, and the narrative response — tariffs, currency, timing — is so far unchallenged.

5. Guidance Track Record

Credibility score: 7/10. What this reflects: the core near-term operating promise machinery is working. Initial outlook has been met or beaten every year the team has owned the Novonesis entity, cost synergies arrived a full year early (rare in large mergers), and the integration milestones cited in FY2023 for FY2024 all landed on time. Against that, four things pull the score below 8: (1) the pre-merger 2025 targets and the "double sales by 2030" headline were quietly retired rather than reconciled; (2) Q4 2025 is the first consensus miss since the merger closed, and the 2026 guide of 5–7% sits at the low end of the just-launched 2030 GROW range; (3) the primary profit KPI changed at the convenient moment, masking a real step-down in EBIT margin and ROIC once goodwill is included; (4) the "exit from certain countries" footnote has quietly become a recurring 1–2 point organic growth headwind without a clear end date.

6. What the Story Is Now

Novonesis today is a different, bigger, and arguably better business than Novozymes was in 2022, but it is telling a simpler story than it used to, and the simplification is doing real work.

What has been de-risked. The merger itself — the single largest source of execution risk in 2022–2024 — is functionally done. Integration milestones delivered, cost synergies at 100% run-rate a year early, sales synergies contributing ~1 pp to growth, no visible cultural blow-up, and the combined portfolio is genuinely more diversified (Food & Beverages 33%, Ag/Energy/Tech 36%, Household Care 19%, Human Health 12%). Underlying organic growth is running in the 6–8% band with a 37%+ adjusted EBITDA margin — a profile that would be an excellent outcome for a specialty chemicals business of this size.

What still looks stretched. The 2030 adjusted ROIC target of ~16% is set excluding goodwill — a choice that matters, because adjusted ROIC including goodwill is 5.6% today and the new Feed Enzyme Alliance acquisition adds another 1.5 bn EUR of goodwill-heavy assets. The 6–9% CAGR target assumes sustained pricing, continued synergy flow, and emerging-markets growth above 10% — the latter was 9% in 2025 (vs 12% in 2024) and ran at just 1% in Q4. Net debt at 1.9x EBITDA is manageable but is financed in part by a bridge loan to be refinanced in 2026 into a rising-rate environment.

What the reader should believe. The operating team has shown it can execute a hard integration and deliver near-term numbers. The portfolio is genuinely differentiated, biosolutions demand is structurally supported, and the innovation pipeline (HMOs, precision proteins, AI-led R&D, next-gen phytase) has real substance rather than slideware.

What the reader should discount. The framing of PPA-related earnings compression as a purely optical issue; the way pre-merger long-term targets were retired without an explicit reconciliation; "exit from certain countries" as a persistent but unquantified drag treated like a one-off; and the strong adjusted EBITDA margin narrative, which is genuine but is also doing more work than the equivalent EBIT margin narrative did pre-merger.